Neuregenix

Neuregenix is a UK life science company focused on regenerative neurobiology, with roots as a University of Birmingham spin-out. Historically, the company developed patented siRNA-based approaches intended to enhance neuron survival and axon regeneration after central nervous system injury, particularly in spinal cord, brain, and retinal injury settings. More recently, Neuregenix has been described as offering preclinical contract research services, including advanced in vivo disease models, biomarker technology, and histology support for neurology and ophthalmology drug discovery programs. Publicly available evidence suggests the legal entity remains active at Companies House, while commercial databases have also described the operating business profile as closed or dormant, so current operating scale appears limited. The company is best characterized as a small neuroscience-focused biotech/CRO hybrid centered on neural repair and translational preclinical services.